Skip to content

Research Areas

Biosfer Teslab has more than 90 publications in multiple research areas. 

Abstract Objectives: To identify potential biomarkers of disease activity analysing the proteome of high-density lipoprotein (HDL) particles from SLE patients in clinical …

Abstract Patients with morbid obesity frequently present non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) associated with pro-atherogenic alterations. Laparoscopic sleeve gastrectomy …

Abstract Objective: Vascular aging (arterial stiffness [AS]) is an inflammation-linked process that predicts macro- and microvascular complications in adults with type 1 diabetes …

The role of inflammation in heart failure (HF) has been extensively described, but it is uncertain whether inflammation exerts a different prognostic …

Background: Heart failure with preserved ejection fraction (HFpEF) is a disorder related to patient comorbidities and aging. Whether mitochondrial dysfunction is present during …

Objective chronic inflammation and immune dysregulation are crucial mechanisms for atherosclerosis in rheumatoid arthritis (RA). Recent evidence suggests a link via humoral …

Background: A 10-month strategy of cardiac telerehabilitation (CTR) improved outcomes over a standard centre-based cardiac rehabilitation (CBCR), as recently published. We hypothesised …

Background and Aims : Patients with type 2 diabetes mellitus (T2DM) and atherogenic dyslipidaemia (AD) are at higher risk of developing cardiovascular …

Background and Aims : Nuclear magnetic resonance (1H-NMR) analysis have recently used to uncover hidden quantitative lipoprotein characteristics in cardiometabolic scenarios. The …

Addressing factors modulating COVID-19 is crucial since abundant clinical evidence shows that outcomes are markedly heterogeneous between patients. This requires identifying the …

ACCIÓ GRANT

BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And  INSULIN RESISTANCE FOR THE IMPROVEMENT OF  CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE”  (RD15-1-0013).

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

In particular, the company has developed a glycoprotein test and a LMWM test - that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.

The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.

This aid is programmed in the axis 1, "Boost research, technological development and innovation", specific objective OE 1.2.2, "Transfer and spreading of technology and cooperation between companies and universities or other research centers", line of action "Collaborative R+D projects" under the framework of the FEDER Operational Program of Catalonia 2014-2020